Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 350Stomach Neoplasms 31Neoplasm Metastasis 30Breast Neoplasms, Male 25Neoplasms 16Inflammatory Breast Neoplasms 12Brain Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Esophageal Neoplasms 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Adenocarcinoma 5Sarcoma 4Lung Neoplasms 4HER2-positive Breast Cancer 4Endometrial Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Head and Neck Neoplasms 3HER2 Positive Breast Cancer 3Cardiotoxicity 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Hepatocellular 3Carcinoma, Ductal, Breast 3

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bladder Urothelial Carcinoma × Trastuzumab × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡